News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Board directors in Egetis Therapeutics acquire shares

June 16, 2023

Stockholm, Sweden, June 16, 2023. Egetis Therapeutics AB (publ) (STO: EGTX) (the “Company”) today announced that Board directors Gunilla Osswald and Elisabeth Svanberg have acquired shares in the Company. On June 15, 2023, Gunilla Osswald acquired 40,000 shares and on June 5, 2023, Elisabeth Svanberg acquired 10 280 shares. Gunilla Osswald’s total holding in the Company amounts to 40,000 shares and Elisabeth Svanberg’s s total holding in the Company now amounts to 37,676 shares.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10